Biogen is pulling out of Sage Therapeutics' SAGE-324 program, adding another wrinkle to their collaboration on neurological treatments. The decision, announced Thursday, comes on the heels of disappointing mid-stage results for the investigational drug in essential tremor (ET) patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,